Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Saketh Guntupalli

Concepts (296)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
22
2025
205
4.780
Why?
Ovarian Neoplasms
17
2026
604
3.020
Why?
Genital Neoplasms, Female
7
2024
100
2.670
Why?
Gynecology
8
2021
185
2.340
Why?
Pyridones
5
2026
210
2.150
Why?
Enoxaparin
4
2024
68
2.120
Why?
Carcinoma, Endometrioid
11
2023
49
2.030
Why?
Hysterectomy
11
2020
139
1.860
Why?
Pyrazoles
4
2024
517
1.680
Why?
Uterine Cervical Neoplasms
8
2021
269
1.590
Why?
Fellowships and Scholarships
5
2018
355
1.580
Why?
Obstetrics
4
2020
179
1.540
Why?
Neoplasm Recurrence, Local
11
2026
1160
1.320
Why?
Poly(ADP-ribose) Polymerase Inhibitors
5
2025
139
1.290
Why?
Venous Thromboembolism
4
2024
332
1.280
Why?
Internship and Residency
6
2020
1281
1.270
Why?
Postoperative Complications
8
2024
3034
1.120
Why?
Anticoagulants
4
2024
746
1.120
Why?
Sexual Dysfunction, Physiological
2
2020
74
1.050
Why?
Lymph Nodes
3
2017
511
1.020
Why?
Clinical Competence
5
2020
1272
0.940
Why?
Neoplasm Staging
19
2025
1488
0.830
Why?
Uterine Neoplasms
3
2021
98
0.770
Why?
Middle Aged
46
2026
36619
0.690
Why?
Female
66
2026
79499
0.690
Why?
Antineoplastic Combined Chemotherapy Protocols
8
2025
1998
0.690
Why?
Treatment Adherence and Compliance
1
2021
27
0.670
Why?
Indoles
1
2025
511
0.670
Why?
Pulmonary Embolism
1
2023
246
0.640
Why?
Aged
36
2026
26432
0.640
Why?
Education, Medical, Graduate
2
2016
568
0.630
Why?
Carcinosarcoma
3
2017
23
0.630
Why?
Intrauterine Devices
1
2019
29
0.590
Why?
Ovariectomy
4
2015
164
0.550
Why?
Robotic Surgical Procedures
3
2016
210
0.550
Why?
Aged, 80 and over
16
2025
8391
0.540
Why?
Laparotomy
2
2015
111
0.540
Why?
Venous Thrombosis
1
2020
199
0.530
Why?
Humans
69
2026
146342
0.530
Why?
Oncologists
1
2018
47
0.520
Why?
Healthcare Disparities
3
2021
733
0.510
Why?
Quality of Health Care
2
2021
702
0.500
Why?
Neoplasm Invasiveness
6
2021
504
0.500
Why?
Sexual Dysfunctions, Psychological
1
2017
29
0.490
Why?
Prognosis
12
2025
4351
0.490
Why?
Neoplasms
6
2024
2954
0.490
Why?
Attitude
1
2018
253
0.480
Why?
Minority Groups
1
2018
286
0.470
Why?
Retrospective Studies
17
2024
17438
0.470
Why?
Medication Adherence
1
2020
535
0.460
Why?
Gynecologic Surgical Procedures
3
2024
68
0.450
Why?
Endometrium
2
2019
64
0.430
Why?
Radiography, Thoracic
1
2016
174
0.430
Why?
Hemostasis, Surgical
1
2014
25
0.420
Why?
Abdominal Abscess
1
2014
28
0.420
Why?
Gelatin
1
2014
56
0.410
Why?
Interpersonal Relations
1
2017
387
0.400
Why?
Surgeons
1
2018
351
0.400
Why?
Adult
30
2026
41087
0.390
Why?
Thrombin
1
2014
175
0.390
Why?
WT1 Proteins
1
2013
12
0.380
Why?
Robotics
1
2014
89
0.380
Why?
Estrogen Receptor beta
1
2013
40
0.370
Why?
Histone-Lysine N-Methyltransferase
2
2024
141
0.370
Why?
Disease-Free Survival
7
2025
778
0.350
Why?
Follow-Up Studies
9
2024
5439
0.350
Why?
Adenocarcinoma
3
2021
927
0.340
Why?
Biomarkers, Tumor
5
2026
1339
0.340
Why?
Lymphatic Vessels
1
2011
64
0.330
Why?
Adenocarcinoma, Clear Cell
2
2023
14
0.320
Why?
Neoplasm Grading
8
2026
313
0.310
Why?
Smooth Muscle Tumor
1
2009
6
0.290
Why?
Lymph Node Excision
3
2017
174
0.290
Why?
Leiomyosarcoma
1
2009
30
0.290
Why?
Preoperative Care
3
2017
396
0.290
Why?
Chemotherapy, Adjuvant
4
2025
429
0.290
Why?
Sarcoma, Alveolar Soft Part
1
2008
6
0.280
Why?
United States
14
2024
16136
0.260
Why?
Survival Rate
6
2021
2092
0.260
Why?
Neoplasms, Second Primary
2
2019
103
0.250
Why?
Radiotherapy, Adjuvant
3
2018
222
0.250
Why?
Combined Modality Therapy
3
2020
1271
0.250
Why?
Insurance, Health
3
2018
318
0.230
Why?
Peritoneum
1
2025
44
0.220
Why?
Maintenance Chemotherapy
1
2025
41
0.220
Why?
Cross-Sectional Studies
5
2017
5899
0.220
Why?
Risk Factors
7
2024
10921
0.220
Why?
Insurance Coverage
2
2018
248
0.220
Why?
Cohort Studies
5
2021
6077
0.220
Why?
Pyrimidinones
1
2026
124
0.220
Why?
Pregnancy Complications
2
2014
609
0.220
Why?
Paclitaxel
6
2024
260
0.220
Why?
Cystadenocarcinoma, Serous
1
2026
90
0.210
Why?
Young Adult
7
2021
14330
0.210
Why?
Lymphatic Metastasis
2
2019
335
0.210
Why?
Databases, Factual
3
2021
1493
0.200
Why?
Doxorubicin
2
2024
416
0.200
Why?
Nomograms
2
2021
59
0.200
Why?
Self Report
2
2018
870
0.200
Why?
Chemoradiotherapy
1
2024
238
0.190
Why?
Immunoglobulin M
1
2024
284
0.190
Why?
Tertiary Care Centers
1
2023
196
0.180
Why?
Lung Neoplasms
1
2016
2675
0.180
Why?
Liver Diseases
1
2005
304
0.180
Why?
Factor Xa Inhibitors
1
2024
195
0.180
Why?
Program Evaluation
2
2018
952
0.180
Why?
Organ Sparing Treatments
2
2019
37
0.180
Why?
Platinum
1
2022
48
0.180
Why?
Enzyme-Linked Immunosorbent Assay
1
2024
846
0.180
Why?
Drug Resistance, Neoplasm
2
2024
893
0.170
Why?
Adolescent
6
2021
22557
0.170
Why?
Immunohistochemistry
2
2023
1712
0.170
Why?
Quality of Life
4
2024
3200
0.170
Why?
Length of Stay
3
2015
1358
0.170
Why?
beta Catenin
2
2023
250
0.160
Why?
BRCA2 Protein
1
2021
69
0.160
Why?
BRCA1 Protein
1
2021
84
0.160
Why?
Ovary
2
2019
236
0.160
Why?
Double-Blind Method
1
2025
2070
0.160
Why?
Risk Assessment
4
2024
3712
0.150
Why?
High-Throughput Nucleotide Sequencing
1
2023
539
0.150
Why?
Fallopian Tube Neoplasms
1
2019
20
0.150
Why?
Immunoglobulin G
1
2024
901
0.150
Why?
Withholding Treatment
1
2020
77
0.150
Why?
Cytoreduction Surgical Procedures
1
2020
69
0.150
Why?
Treatment Outcome
5
2020
11821
0.150
Why?
NM23 Nucleoside Diphosphate Kinases
1
2019
2
0.150
Why?
Postoperative Hemorrhage
1
2020
106
0.150
Why?
Polyethylene Glycols
1
2024
650
0.140
Why?
Age Factors
4
2016
3347
0.140
Why?
Peritoneal Neoplasms
1
2019
103
0.140
Why?
Cisplatin
4
2024
347
0.140
Why?
Incidence
3
2024
2936
0.140
Why?
CD8-Positive T-Lymphocytes
1
2024
931
0.140
Why?
Pregnancy
4
2020
7230
0.140
Why?
Mutation
3
2026
4093
0.130
Why?
Stathmin
1
2017
2
0.130
Why?
Fibrinolytic Agents
1
2020
303
0.130
Why?
Carcinoma, Adenosquamous
1
2017
9
0.130
Why?
Carboplatin
3
2024
168
0.130
Why?
Cancer Survivors
1
2023
348
0.130
Why?
Carcinoma
1
2019
225
0.120
Why?
Randomized Controlled Trials as Topic
2
2021
1763
0.120
Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2017
27
0.120
Why?
Blood Loss, Surgical
2
2015
117
0.120
Why?
Guideline Adherence
1
2021
594
0.120
Why?
Neoadjuvant Therapy
1
2020
475
0.120
Why?
Socioeconomic Factors
1
2021
1327
0.120
Why?
Societies, Medical
1
2021
907
0.120
Why?
National Cancer Institute (U.S.)
1
2016
56
0.120
Why?
Case-Control Studies
4
2019
3647
0.120
Why?
Carcinoma, Squamous Cell
2
2021
628
0.120
Why?
Health Status Disparities
2
2017
322
0.120
Why?
Benzamides
1
2017
226
0.120
Why?
Uterus
2
2023
227
0.120
Why?
Surgical Oncology
1
2016
30
0.120
Why?
Neonatology
1
2016
36
0.120
Why?
Reimbursement Mechanisms
1
2016
79
0.110
Why?
Marriage
1
2017
122
0.110
Why?
Piperidines
1
2017
225
0.110
Why?
Perioperative Care
1
2018
235
0.110
Why?
Bevacizumab
3
2021
169
0.110
Why?
Prospective Studies
7
2025
8123
0.110
Why?
Drug Costs
1
2016
116
0.110
Why?
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
2015
22
0.110
Why?
Pneumonia, Viral
1
2020
387
0.110
Why?
Coronavirus Infections
1
2020
379
0.110
Why?
Female Urogenital Diseases
1
2014
8
0.110
Why?
Pregnancy Complications, Neoplastic
1
2015
64
0.110
Why?
Morbidity
1
2015
319
0.110
Why?
Peritoneal Cavity
1
2014
30
0.100
Why?
Blood Volume
1
2014
57
0.100
Why?
Surgical Wound Dehiscence
1
2014
22
0.100
Why?
Intraoperative Complications
1
2015
157
0.100
Why?
Maternal-Fetal Exchange
1
2015
171
0.100
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2017
344
0.100
Why?
Hemostatics
1
2014
66
0.100
Why?
Colposcopy
1
2013
18
0.100
Why?
Drainage
1
2014
187
0.100
Why?
Health Policy
1
2016
399
0.090
Why?
Antibodies
1
2015
400
0.090
Why?
Needs Assessment
1
2015
404
0.090
Why?
Patient Readmission
1
2018
778
0.090
Why?
Referral and Consultation
1
2018
881
0.090
Why?
DNA Polymerase II
2
2023
35
0.090
Why?
Poly-ADP-Ribose Binding Proteins
2
2023
35
0.090
Why?
Pandemics
1
2020
1707
0.080
Why?
Proportional Hazards Models
3
2021
1331
0.080
Why?
Clinical Trials as Topic
1
2016
1064
0.080
Why?
Surgical Wound Infection
1
2014
349
0.080
Why?
Early Detection of Cancer
1
2016
506
0.080
Why?
Fetus
1
2015
800
0.080
Why?
Kaplan-Meier Estimate
1
2013
970
0.080
Why?
Multivariate Analysis
1
2013
1543
0.070
Why?
Benzimidazoles
2
2021
191
0.070
Why?
Metrorrhagia
1
2008
4
0.070
Why?
Dilatation and Curettage
1
2008
13
0.070
Why?
Multicenter Studies as Topic
2
2021
417
0.070
Why?
Pediatrics
1
2016
1124
0.070
Why?
Surveys and Questionnaires
2
2018
6073
0.070
Why?
Tumor Suppressor Protein p53
2
2023
530
0.060
Why?
Male
7
2024
73396
0.060
Why?
SEER Program
2
2018
233
0.060
Why?
Quality Improvement
1
2015
1354
0.060
Why?
Models, Biological
1
2014
1761
0.060
Why?
Cell Line, Tumor
2
2024
3545
0.060
Why?
Rupture, Spontaneous
1
2005
14
0.060
Why?
Budd-Chiari Syndrome
1
2005
5
0.060
Why?
HELLP Syndrome
1
2005
5
0.060
Why?
Hepatolenticular Degeneration
1
2005
15
0.060
Why?
Hematoma
1
2005
62
0.060
Why?
Hepatitis B
1
2005
66
0.050
Why?
Histocompatibility Antigens
1
2024
102
0.050
Why?
Cost-Benefit Analysis
2
2020
640
0.050
Why?
Obesity
2
2016
3131
0.050
Why?
Colorado
1
2014
4595
0.050
Why?
Tomography, X-Ray Computed
1
2014
2786
0.050
Why?
Anti-Bacterial Agents
1
2014
1942
0.050
Why?
DNA Mismatch Repair
1
2023
54
0.050
Why?
Pre-Eclampsia
1
2005
206
0.050
Why?
Cholestasis
1
2005
217
0.050
Why?
Fatty Liver
1
2005
252
0.050
Why?
Hepatitis C
1
2005
251
0.050
Why?
Decision Support Techniques
2
2020
478
0.050
Why?
Acute Disease
1
2005
1038
0.050
Why?
X-ray Repair Cross Complementing Protein 1
1
2022
14
0.050
Why?
Medical Futility
1
2022
32
0.040
Why?
Claudin-4
1
2022
18
0.040
Why?
Liposomes
1
2024
269
0.040
Why?
Genes, BRCA2
1
2021
33
0.040
Why?
Clinical Trials, Phase I as Topic
1
2021
49
0.040
Why?
Genes, BRCA1
1
2021
45
0.040
Why?
Xenograft Model Antitumor Assays
1
2024
930
0.040
Why?
Hematologic Diseases
1
2021
66
0.040
Why?
Topotecan
1
2020
17
0.040
Why?
Organoplatinum Compounds
1
2020
65
0.040
Why?
Quality-Adjusted Life Years
1
2020
122
0.040
Why?
Life Style
1
2023
496
0.040
Why?
Injections, Intraperitoneal
1
2019
115
0.040
Why?
DNA Repair
1
2022
255
0.040
Why?
Injections, Intravenous
1
2019
197
0.040
Why?
Critical Care
1
2005
706
0.040
Why?
Japan
1
2019
149
0.040
Why?
Platinum Compounds
1
2019
10
0.040
Why?
DNA Damage
1
2022
439
0.040
Why?
Infusions, Intravenous
1
2020
432
0.040
Why?
Microsatellite Instability
1
2019
57
0.040
Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
111
0.030
Why?
Angiogenesis Inhibitors
1
2020
239
0.030
Why?
Gene Expression Regulation, Neoplastic
1
2024
1432
0.030
Why?
PTEN Phosphohydrolase
1
2019
166
0.030
Why?
Antineoplastic Agents, Phytogenic
1
2019
178
0.030
Why?
Survival Analysis
1
2021
1378
0.030
Why?
Administration, Oral
1
2020
872
0.030
Why?
Betacoronavirus
1
2020
288
0.030
Why?
Mice
2
2024
18297
0.030
Why?
Cell Proliferation
1
2024
2502
0.030
Why?
Hospitals, Private
1
2016
12
0.030
Why?
Health Facility Size
1
2016
13
0.030
Why?
Time Factors
2
2017
7109
0.030
Why?
Hospitals, Teaching
1
2016
121
0.030
Why?
Social Class
1
2017
260
0.030
Why?
Odds Ratio
1
2018
1077
0.030
Why?
ErbB Receptors
1
2019
636
0.030
Why?
Patient Reported Outcome Measures
1
2020
516
0.030
Why?
Medically Uninsured
1
2016
134
0.030
Why?
Dose-Response Relationship, Drug
1
2019
2022
0.030
Why?
Ileus
1
2015
14
0.030
Why?
Salpingectomy
1
2015
15
0.030
Why?
Urinary Retention
1
2015
23
0.030
Why?
Diet
1
2023
1273
0.030
Why?
Income
1
2016
206
0.030
Why?
Advisory Committees
1
2016
228
0.030
Why?
Elective Surgical Procedures
1
2016
216
0.030
Why?
Pelvis
1
2015
129
0.020
Why?
Disease Models, Animal
1
2024
4580
0.020
Why?
Papanicolaou Test
1
2013
35
0.020
Why?
Vaginal Smears
1
2013
54
0.020
Why?
Critical Pathways
1
2014
104
0.020
Why?
Urban Population
1
2016
497
0.020
Why?
Membrane Proteins
1
2019
1130
0.020
Why?
Clinical Protocols
1
2014
282
0.020
Why?
Animals
2
2024
38107
0.020
Why?
Pregnancy Outcome
1
2015
503
0.020
Why?
Polymorphism, Single Nucleotide
1
2019
2240
0.020
Why?
Comorbidity
1
2016
1665
0.020
Why?
Disease Progression
1
2019
2867
0.020
Why?
Rural Population
1
2016
677
0.020
Why?
Exercise
1
2023
2213
0.020
Why?
Biomedical Research
1
2016
729
0.020
Why?
Curriculum
1
2016
1079
0.020
Why?
Prostatic Neoplasms
1
2016
972
0.020
Why?
Patient Discharge
1
2015
997
0.020
Why?
Colorectal Neoplasms
1
2016
874
0.020
Why?
Infant, Newborn
1
2015
6460
0.010
Why?
Breast Neoplasms
1
2016
2418
0.010
Why?
Guntupalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)